Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment.
cancer
immune cells
immunomodulation
resveratrol
tumor microenvironment
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
03 Mar 2021
03 Mar 2021
Historique:
received:
13
01
2021
revised:
25
02
2021
accepted:
25
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
19
5
2021
Statut:
epublish
Résumé
Immunomodulation of the tumor microenvironment is emerging as an important area of research for the treatment of cancer patients. Several synthetic and natural agents are being investigated for their ability to enhance the immunogenic responses of immune cells present in the tumor microenvironment to impede tumor cell growth and dissemination. Among them, resveratrol, a stilbenoid found in red grapes and many other natural sources, has been studied extensively. Importantly, resveratrol has been shown to possess activity against various human diseases, including cancer. Mechanistically, resveratrol has been shown to regulate an array of signaling pathways and processes involving oxidative stress, inflammation, apoptosis, and several anticancer effects. Furthermore, recent research suggests that resveratrol can regulate various cellular signaling events including immune cell regulation, cytokines/chemokines secretion, and the expression of several other immune-related genes. In this review, we have summarized recent findings on resveratrol's effects on immune regulatory cells and associated signaling in various cancer types. Numerous immunomodulatory effects of resveratrol suggest it may be useful in combination with other cancer therapies including immunotherapy for effective cancer management.
Identifiants
pubmed: 33802331
pii: molecules26051343
doi: 10.3390/molecules26051343
pmc: PMC7959117
pii:
doi:
Substances chimiques
Antioxidants
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Veterans Affairs
ID : I01CX001441, 1I01BX004221, IK6BX003780
Organisme : NIH HHS
ID : R01AR059130
Pays : United States
Organisme : BLRD VA
ID : IK6 BX003780
Pays : United States
Organisme : CSRD VA
ID : I01 CX001441
Pays : United States
Organisme : BLRD VA
ID : I01 BX004221
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR059130
Pays : United States
Références
Semin Cancer Biol. 2016 Oct;40-41:209-232
pubmed: 26774195
Int J Oncol. 2020 Jun;56(6):1405-1416
pubmed: 32236622
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Molecules. 2017 Feb 14;22(2):
pubmed: 28216605
Biochem Soc Trans. 2007 Nov;35(Pt 5):1156-60
pubmed: 17956300
Science. 1997 Jan 10;275(5297):218-20
pubmed: 8985016
Trends Immunol. 2016 Dec;37(12):855-865
pubmed: 27793569
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Int Immunopharmacol. 2012 Nov;14(3):328-33
pubmed: 22884509
BMC Immunol. 2018 Feb 02;19(1):7
pubmed: 29390972
Int J Oncol. 2003 Jul;23(1):17-28
pubmed: 12792772
J Innate Immun. 2021;13(2):94-106
pubmed: 32937636
Pharm Res. 2010 Jun;27(6):979-88
pubmed: 20119749
J Pineal Res. 2011 Mar;50(2):140-9
pubmed: 21062352
Ann N Y Acad Sci. 2011 Jan;1215:79-88
pubmed: 21261644
J Cancer Res Clin Oncol. 2021 Apr;147(4):1101-1113
pubmed: 33471184
Ann N Y Acad Sci. 2013 Jul;1290:113-21
pubmed: 23855473
Biochem Pharmacol. 2007 Dec 3;74(11):1568-74
pubmed: 17868649
Med Chem. 2006 May;2(3):275-85
pubmed: 16948474
Curr Pharm Des. 2019;25(12):1345-1371
pubmed: 30968773
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Nutrients. 2018 Dec 03;10(12):
pubmed: 30513922
Int J Oncol. 2018 Oct;53(4):1469-1480
pubmed: 30066852
Front Oncol. 2018 Mar 12;8:49
pubmed: 29594035
Aging (Albany NY). 2020 Jan 4;12(1):8-34
pubmed: 31901900
Crit Rev Food Sci Nutr. 2018 Jun 13;58(9):1428-1447
pubmed: 28001084
J Dent Sci. 2019 Sep;14(3):255-262
pubmed: 31528253
Nutr Cancer. 2016 May-Jun;68(4):667-78
pubmed: 27145432
Nutrients. 2019 Apr 26;11(5):
pubmed: 31035454
Endocr Metab Immune Disord Drug Targets. 2015;15(3):186-95
pubmed: 25772176
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Int J Mol Sci. 2020 Dec 16;21(24):
pubmed: 33339133
Mol Ther Oncolytics. 2019 Nov 29;16:41-52
pubmed: 31930165
Mol Nutr Food Res. 2016 Jun;60(6):1406-15
pubmed: 26829056
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Ann N Y Acad Sci. 2011 Jan;1215:144-9
pubmed: 21261653
Ann N Y Acad Sci. 2011 Jan;1215:150-60
pubmed: 21261654
Ann N Y Acad Sci. 2015 Aug;1348(1):150-60
pubmed: 26099945
Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75
pubmed: 20716633
Antioxid Redox Signal. 2018 Mar 10;28(8):643-661
pubmed: 28891317
Infect Agent Cancer. 2019 Oct 18;14:27
pubmed: 31636696
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925765
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194365
Molecules. 2017 Jun 18;22(6):
pubmed: 28629161
Int Immunopharmacol. 2014 Oct;22(2):303-10
pubmed: 25042796
Mol Cancer Ther. 2006 May;5(5):1335-41
pubmed: 16731767
PLoS One. 2010 Dec 14;5(12):e15288
pubmed: 21179458
Oncoimmunology. 2020 Oct 24;9(1):1829346
pubmed: 33150044
Arch Pharm Res. 2001 Dec;24(6):597-600
pubmed: 11794542
Cell Cycle. 2014;13(4):632-40
pubmed: 24343700
Int Immunopharmacol. 2020 Nov;88:106905
pubmed: 32905970
Nutr J. 2016 May 04;15(1):47
pubmed: 27142426
Oncotarget. 2017 Jul 22;8(39):65743-65758
pubmed: 29029468
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
Biochem Pharmacol. 2009 Apr 15;77(8):1337-47
pubmed: 19426672
Arch Biochem Biophys. 2011 Apr 15;508(2):164-70
pubmed: 21215251
Biochim Biophys Acta. 2015 Jun;1852(6):1178-85
pubmed: 25446990
BMC Cancer. 2020 Jun 29;20(1):603
pubmed: 32600429
Cancer Manag Res. 2019 Dec 24;11:10731-10747
pubmed: 31920383
Cancer Lett. 2018 May 28;422:9-18
pubmed: 29471004
Photochem Photobiol. 2008 Mar-Apr;84(2):415-21
pubmed: 18221451
Cell Immunol. 2017 Jan;311:86-93
pubmed: 27825563
Arch Biochem Biophys. 2014 Dec 1;563:94-100
pubmed: 24751483